公开(公告)号：US20240033278A9

公开(公告)日：2024-02-01

申请号：US18001429

申请日：2021-06-10

申请人： MEDSHINE DISCOVERY INC.

发明人： Ke AN ,  Fei SUN ,  Charles Z. DING ,  Shuhui CHEN

IPC分类号： A61K31/7088 ,  A61K47/54 ,  C12N15/113

CPC分类号： A61K31/7088 ,  A61K47/54 ,  C12N15/113

摘要： The present application relates to a novel conjugate group linkable to a compound (such as a therapeutic compound), for use in directing the compound to a target in the body. The conjugate group disclosed herein can enable an expression-inhibitory oligonucleotide (such as a RNAi reagent) to target liver cells to regulate gene expression. The conjugate group disclosed herein has a variety of applications when linked to expression-inhibitory oligonucleotides, comprising applications in therapy, diagnosis, target verification, and genome development. A composition comprising the conjugate group disclosed herein can mediate expression of target nucleic acid sequences in liver cells (such as hepatocytes) when linked to expression-inhibitory oligonucleotides, and can be used for treatment of diseases or disorders responding to the gene expression or activity of cells, tissues, or organisms.

公开(公告)号：US20230348503A1

公开(公告)日：2023-11-02

申请号：US18044791

申请日：2021-09-15

申请人： MEDSHINE DISCOVERY INC.

发明人： Zhe CAI ,  Fei SUN ,  Charles Z. DING ,  Shuhui CHEN

IPC分类号： C07F9/6558 ,  A61P35/00

CPC分类号： C07F9/65586 ,  A61P35/00

摘要： Provided is an isochroman compound represented by formula (I), or a pharmaceutically acceptable salt thereof, which is used as an aldo-keto reductase (AKR1C3) inhibitor for the treatment of liver cancer.

公开(公告)号：US20230235330A1

公开(公告)日：2023-07-27

申请号：US18001244

申请日：2021-06-07

申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. ,  MEDSHINE DISCOVERY INC.

发明人： Ke AN ,  Fei SUN ,  Charles Z. DING ,  Shuhui CHEN

IPC分类号： C12N15/113 ,  A61P31/20 ,  A61K31/713 ,  A61K47/54

CPC分类号： C12N15/1131 ,  A61P31/20 ,  A61K31/713 ,  A61K47/549 ,  C12N2310/14 ,  C12N2310/351 ,  C12N2310/315 ,  C12N2310/314

摘要： Provided are a double-stranded siRNA analogue embedded with a ribavirin derivative, a conjugate containing same, and a salt and the use thereof. The provided double-stranded siRNA analogue, the conjugate containing same and the salt thereof can effectively inhibit multiple viral indicators such as hepatitis B virus DNA, pgRNA, S antigen, and E antigen, which provide an effective and feasible method for treating hepatitis B.

公开(公告)号：US20230210882A1

公开(公告)日：2023-07-06

申请号：US18001429

申请日：2021-06-10

申请人： MEDSHINE DISCOVERY INC.

发明人： Ke AN ,  Fei SUN ,  Charles Z. DING ,  Shuhui CHEN

IPC分类号： A61K31/7088 ,  A61K47/54 ,  C12N15/113

CPC分类号： A61K31/7088 ,  A61K47/54 ,  C12N15/113

摘要： The present application relates to a novel conjugate group linkable to a compound (such as a therapeutic compound), for use in directing the compound to a target in the body. The conjugate group disclosed herein can enable an expression-inhibitory oligonucleotide (such as a RNAi reagent) to target liver cells to regulate gene expression. The conjugate group disclosed herein has a variety of applications when linked to expression-inhibitory oligonucleotides, comprising applications in therapy, diagnosis, target verification, and genome development. A composition comprising the conjugate group disclosed herein can mediate expression of target nucleic acid sequences in liver cells (such as hepatocytes) when linked to expression-inhibitory oligonucleotides, and can be used for treatment of diseases or disorders responding to the gene expression or activity of cells, tissues, or organisms.

公开(公告)号：US20180222886A1

公开(公告)日：2018-08-09

申请号：US15750704

申请日：2016-08-03

申请人： MEDSHINE DISCOVERY INC. ,  HARBIN ZHENBAO PHARMACEUTICAL CO., LTD.

发明人： Shuhui CHEN ,  Zhengxia CHEN ,  Meibi DAI ,  Cheng XIE ,  Peng LI ,  Yang ZHANG ,  Guibai LIANG ,  Qiang WANG ,  Jiangpeng LIAO ,  Fei SUN ,  Guoping HU ,  Jian LI

IPC分类号： C07D401/14 ,  C07D405/14 ,  C07D401/12 ,  C07D413/14 ,  A61P35/00

摘要： FGFR and VEGFR inhibitors are provided, and compounds represented by formula (1) or formula (II) as FGFR and VEGFR inhibitors, pharmaceutically acceptable salts or tautomers thereof are specifically disclosed.

公开(公告)号：US20230265090A1

公开(公告)日：2023-08-24

申请号：US18005347

申请日：2021-07-23

申请人： MEDSHINE DISCOVERY INC.

发明人： Lifang WU ,  Fei SUN ,  Charles Z. DING ,  Shuhui CHEN

IPC分类号： C07D471/04 ,  C07D519/00 ,  A61P35/00

CPC分类号： C07D471/04 ,  C07D519/00 ,  A61P35/00

摘要： A quinazoline compound and a pharmaceutically acceptable salt thereof, in particular a compound of formula (II) and a pharmaceutically acceptable salt thereof.

公开(公告)号：US20200039995A1

公开(公告)日：2020-02-06

申请号：US16491769

申请日：2018-03-09

申请人： FUJIAN COSUNTER PHARMACEUTICAL CO., LTD. ,  MEDSHINE DISCOVERY INC.

发明人： Fei SUN ,  Jinhua DU ,  Yanbin HU ,  Lili ZHOU ,  Charles Z. DING ,  Shuhhui CHEN

IPC分类号： C07D491/052 ,  A61P31/20

摘要： 10-oxo-6,1-dihydrobenzo[e]pyrido[1,2-c][1,3]oxazine-9-carboxylic acid derivatives of formula (I) as hepatitis B surface antigen inhibitors or pharmaceutically acceptable salts thereof, and uses of a compound of formula (I) or pharmaceutically acceptable salts thereof and pharmaceutical compositions thereof in preparation of medicaments for treatment of viral hepatitis B.

公开(公告)号：US20190151299A1

公开(公告)日：2019-05-23

申请号：US16308859

申请日：2017-06-08

申请人： GENFLEET THERAPEUTICS (SHANGHAI) INC. ,  MEDSHINE DISCOVERY INC.

发明人： Fei SUN ,  Lifang WU ,  Charles Z. DING ,  Guoping HU ,  Jian LI ,  Shuhui CHEN ,  Jianyu LU

IPC分类号： A61K31/4439 ,  A61P35/00

摘要： A benzotriazole-derived α and β-unsaturated amide compound used as TGF-βR1 inhibitor or a pharmaceutically acceptable salt thereof, the structure of the compound being as shown in formula (I).

公开(公告)号：US20180148452A1

公开(公告)日：2018-05-31

申请号：US15573990

申请日：2015-12-29

申请人： MEDSHINE DISCOVERY INC.

发明人： Charles Z. DING ,  Fei SUN ,  Lifang WU ,  Jinhua DU ,  Yasuhiro KATSU ,  Guoping HU ,  Jian LI

IPC分类号： C07D487/04 ,  C07D519/00 ,  A61P35/00 ,  A61P37/08 ,  A61P11/06

CPC分类号： C07D487/04 ,  A61K31/519 ,  A61P11/06 ,  A61P35/00 ,  A61P37/08 ,  C07D519/00

摘要： Disclosed are a novel pyrrolopyrimidine ring compound as a TLR7 agonist or a pharmaceutically acceptable salt thereof, used for preventing or treating allergic rhinitis and asthma. In particular, disclosed is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240217953A1

公开(公告)日：2024-07-04

申请号：US18286326

申请日：2022-04-15

申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. ,  MEDSHINE DISCOVERY INC.

发明人： Charles Z DING ,  Xiaobing YAN ,  Fei SUN ,  Wen JIANG ,  Jian LI ,  Shuhui CHEN

IPC分类号： C07D403/06 ,  A61K31/404 ,  A61K31/439 ,  A61K31/4439 ,  C07D401/14 ,  C07D471/08 ,  C07D491/08

CPC分类号： C07D403/06 ,  A61K31/404 ,  A61K31/439 ,  A61K31/4439 ,  C07D401/14 ,  C07D471/08 ,  C07D491/08

摘要： A bicyclic substituted aromatic carboxylic acid compound, in particular a compound as represented by formula (I) and a pharmaceutically acceptable salt thereof. In formula (I), R2 and R3 and atoms connected thereto together form a 3-6 membered heterocyclic group, or R2 and R4 and atoms connected thereto together form a 3-6 membered heterocyclic group. The compound has obvious inhibitory activity on activation of a human serum alternative pathway and significant binding activity to human complement Factor B protein, and also has relatively good in-vivo pharmacodynamic and pharmacokinetic properties.